Other Species / Isoforms
  cPLA2 (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsFIDPYQH
Upstream
0 4
Treatment
  • IL-33
cPLA2 (human) ______MsFIDPyQH S2-p
cPLA2 (mouse) ______MsFIDPYQH S2-p
cPLA2 (rat) ______MSFIDPYQH S2
Y7
_MsFIDPYQHIIVEH
0 1
cPLA2 (human) _MsFIDPyQHIIVEH Y7-p
cPLA2 (mouse) _MsFIDPYQHIIVEH Y7
cPLA2 (rat) _MSFIDPYQHIIVEH Y7
T21
HQYSHKFTVVVLRAT
0 1
cPLA2 (human) HQYSHKFtVVVLRAT T21-p
cPLA2 (mouse) HQYSHKFTVVVLRAT T21
cPLA2 (rat) HQYSHKFTVVVLRAT T21
T31
VLRATKVTKGTFGDM
0 1
cPLA2 (human) VLRATKVtkGAFGDM T31-p
cPLA2 (mouse) VLRATKVTKGTFGDM T31
cPLA2 (rat) VLRATKVTKGTFGDM T31
K32
LRATKVTKGTFGDML
0 3
cPLA2 (human) LRATKVtkGAFGDML K32-ub
cPLA2 (mouse) LRATKVTKGTFGDML K32
cPLA2 (rat) LRATKVTKGTFGDML K32
Y96-p
ITLMDANyVMDEtLG
0 1
cPLA2 (human) ITLMDANYVMDETLG Y96
cPLA2 (mouse) ITLMDANyVMDEtLG Y96-p
cPLA2 (rat) ITLMDANYVMDETLG Y96
T101-p
ANyVMDEtLGtATFP
0 1
cPLA2 (human) ANYVMDETLGTATFT T101
cPLA2 (mouse) ANyVMDEtLGtATFP T101-p
cPLA2 (rat) ANYVMDETLGTATFP T101
T104-p
VMDEtLGtATFPVSS
0 1
cPLA2 (human) VMDETLGTATFTVSS T104
cPLA2 (mouse) VMDEtLGtATFPVSS T104-p
cPLA2 (rat) VMDETLGTATFPVSS T104
K155
MALCDQEKtFRQQRK
0 2
cPLA2 (human) MALCDQEktFRQQRK K155-ub
cPLA2 (mouse) MALCDQEKtFRQQRK K155
cPLA2 (rat) MALCDQEKTFRRQRK K155
T156-p
ALCDQEKtFRQQRKE
0 1
cPLA2 (human) ALCDQEktFRQQRKE T156-p
cPLA2 (mouse) ALCDQEKtFRQQRKE T156-p
cPLA2 (rat) ALCDQEKTFRRQRKE T156
K171-ac
NIKENMKkLLGPKKS
0 2
cPLA2 (human) HIRESMKkLLGPkNs K171-ac
cPLA2 (mouse) NIKENMKkLLGPKKS K171-ac
cPLA2 (rat) NIKENMKKLLGPKKS K171
K176
MKkLLGPKKSEGLYS
0 1
cPLA2 (human) MKkLLGPkNsEGLHs K176-ac
cPLA2 (mouse) MKkLLGPKKSEGLYS K176
cPLA2 (rat) MKKLLGPKKSEGLYS K176
K176
MKkLLGPKKSEGLYS
0 1
cPLA2 (human) MKkLLGPkNsEGLHs K176-ub
cPLA2 (mouse) MKkLLGPKKSEGLYS K176
cPLA2 (rat) MKKLLGPKKSEGLYS K176
S178
kLLGPKKSEGLYSTR
0 1
cPLA2 (human) kLLGPkNsEGLHsAR S178-p
cPLA2 (mouse) kLLGPKKSEGLYSTR S178
cPLA2 (rat) KLLGPKKSEGLYSTR S178
S183
KKSEGLYSTRDVPVV
0 1
cPLA2 (human) kNsEGLHsARDVPVV S183-p
cPLA2 (mouse) KKSEGLYSTRDVPVV S183
cPLA2 (rat) KKSEGLYSTRDVPVV S183
S228
ATYIAGLSGSTWYMS
4 0
cPLA2 (human) ATYVAGLsGSTWYMS S228-p
cPLA2 (mouse) ATYIAGLSGSTWYMS S228
cPLA2 (rat) ATYVAGLsGSTWYMS S228-p
K257
EINEELMKNVSHNPL
0 1
cPLA2 (human) EINEELMkNVSHNPL K257-ub
cPLA2 (mouse) EINEELMKNVSHNPL K257
cPLA2 (rat) EINEELMKNVSHNPL K257
T268-p
HNPLLLLtPQKVKRY
Upstream
0 12
Regulatory protein:
  • MPRIP (mouse)
cPLA2 (human) HNPLLLLtPQkVkRY T268-p
cPLA2 (mouse) HNPLLLLtPQKVKRY T268-p
cPLA2 (rat) HNPLLLLTPQKVKRY T268
K271
LLLLtPQKVKRYVES
0 1
cPLA2 (human) LLLLtPQkVkRYVES K271-ub
cPLA2 (mouse) LLLLtPQKVKRYVES K271
cPLA2 (rat) LLLLTPQKVKRYVES K271
K273
LLtPQKVKRYVESLW
0 1
cPLA2 (human) LLtPQkVkRYVESLW K273-ub
cPLA2 (mouse) LLtPQKVKRYVESLW K273
cPLA2 (rat) LLTPQKVKRYVESLW K273
K281
RYVESLWKKKSSGQP
0 1
cPLA2 (human) RYVESLWkKkSSGQP K281-ub
cPLA2 (mouse) RYVESLWKKKSSGQP K281
cPLA2 (rat) RYVESLWKKKSSGQP K281
K283
VESLWKKKSSGQPVT
0 1
cPLA2 (human) VESLWkKkSSGQPVT K283-ub
cPLA2 (mouse) VESLWKKKSSGQPVT K283
cPLA2 (rat) VESLWKKKSSGQPVT K283
K316
SMTLSSLKEKVNAAR
0 5
cPLA2 (human) NTTLSSLkEKVNTAQ K316-ub
cPLA2 (mouse) SMTLSSLKEKVNAAR K316
cPLA2 (rat) STTLSSLKEKVSAAR K316
Y359
YEIGMAKYGTFMAPD
0 1
cPLA2 (human) YEIGMAKyGTFMAPD Y359-p
cPLA2 (mouse) YEIGMAKYGTFMAPD Y359
cPLA2 (rat) YEIGMAKYGTFMTPD Y359
S370
MAPDLFGSkFFMGTV
0 1
cPLA2 (human) MAPDLFGskFFMGTV S370-p
cPLA2 (mouse) MAPDLFGSkFFMGTV S370
cPLA2 (rat) MTPDLFGSKFFMGTV S370
K371-ub
APDLFGSkFFMGTVV
0 8
cPLA2 (human) APDLFGskFFMGTVV K371-ub
cPLA2 (mouse) APDLFGSkFFMGTVV K371-ub
cPLA2 (rat) TPDLFGSKFFMGTVV K371
N412
LGVSGSQNKGSTMEE
0 1
cPLA2 (human) LGVSGSQsRGSTMEE S412-p
cPLA2 (mouse) LGVSGSQNKGSTMEE N412
cPLA2 (rat) LGVSGSQNKGSTMEE N412
S431-p
ITAKHIVsNDssDsD
0 7
cPLA2 (human) ITTKHIVsNDssDsD S431-p
cPLA2 (mouse) ITAKHIVsNDssDsD S431-p
cPLA2 (rat) ITAKHIVSNDssDsD S431
S434-p
KHIVsNDssDsDDEA
0 23
cPLA2 (human) KHIVsNDssDsDDEs S434-p
cPLA2 (mouse) KHIVsNDssDsDDEA S434-p
cPLA2 (rat) KHIVSNDssDsDDEA S434-p
S435-p
HIVsNDssDsDDEAQ
0 23
cPLA2 (human) HIVsNDssDsDDEsH S435-p
cPLA2 (mouse) HIVsNDssDsDDEAQ S435-p
cPLA2 (rat) HIVSNDssDsDDEAQ S435-p
S437-p
VsNDssDsDDEAQGP
Upstream
2 52
Regulatory protein:
  • MPRIP (mouse)
  • RICTOR (mouse)
Treatment
  • IFN-gamma
cPLA2 (human) VsNDssDsDDEsHEP S437-p
cPLA2 (mouse) VsNDssDsDDEAQGP S437-p
cPLA2 (rat) VSNDssDsDDEAQGP S437-p
A441
ssDsDDEAQGPKGtE
0 2
cPLA2 (human) ssDsDDEsHEPKGtE S441-p
cPLA2 (mouse) ssDsDDEAQGPKGtE A441
cPLA2 (rat) ssDsDDEAQGPKGTE A441
T447-p
EAQGPKGtENEEAEK
0 2
cPLA2 (human) EsHEPKGtENEDAGs T447-p
cPLA2 (mouse) EAQGPKGtENEEAEK T447-p
cPLA2 (rat) EAQGPKGTENEDAER T447
K454
tENEEAEKEyQSDNQ
2 5
cPLA2 (human) tENEDAGsDyQsDNQ S454-p
cPLA2 (mouse) tENEEAEKEyQSDNQ K454
cPLA2 (rat) TENEDAEREYQNDNQ R454
Y456-p
NEEAEKEyQSDNQAS
0 8
cPLA2 (human) NEDAGsDyQsDNQAs Y456-p
cPLA2 (mouse) NEEAEKEyQSDNQAS Y456-p
cPLA2 (rat) NEDAEREYQNDNQAS Y456
S458
EAEKEyQSDNQASWV
0 1
cPLA2 (human) DAGsDyQsDNQAsWI S458-p
cPLA2 (mouse) EAEKEyQSDNQASWV S458
cPLA2 (rat) DAEREYQNDNQASWV N458
S463
yQSDNQASWVHRMLM
0 1
cPLA2 (human) yQsDNQAsWIHRMIM S463-p
cPLA2 (mouse) yQSDNQASWVHRMLM S463
cPLA2 (rat) YQNDNQASWVHRMLM S463
S505-p
LNTSYPLsPLRDFss
Upstream
Downstream
22 14
cPLA2 (human)
S505-p
cPLA2 (mouse)
S505-p
cPLA2 (rat)
S505-p
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • ERK1 (mouse)
  • ERK2 (mouse)
Treatment
  • A23187
  • anisomycin
  • insulin
  • okadaic_acid
  • SB202190
  • U0126
  • zymosan
cPLA2 (human) LNTSYPLsPLSDFAT S505-p
cPLA2 (mouse) LNTSYPLsPLRDFss S505-p
cPLA2 (rat) LNTSYPLsPLRDFsP S505-p
S511-p
LsPLRDFssQDsFDD
0 2
cPLA2 (human) LsPLSDFATQDsFDD A511
cPLA2 (mouse) LsPLRDFssQDsFDD S511-p
cPLA2 (rat) LsPLRDFsPQDsFDD S511-p
S512-p
sPLRDFssQDsFDDE
0 2
cPLA2 (human) sPLSDFATQDsFDDD T512
cPLA2 (mouse) sPLRDFssQDsFDDE S512-p
cPLA2 (rat) sPLRDFsPQDsFDDD P512
S515-p
RDFssQDsFDDELdA
Upstream
3 6
Regulatory protein:
  • TSC2 (mouse)
Treatment
  • insulin
cPLA2 (human) SDFATQDsFDDDELD S515-p
cPLA2 (mouse) RDFssQDsFDDELdA S515-p
cPLA2 (rat) RDFsPQDsFDDDELD S515-p
D521-ca
DsFDDELdAAVADPD
0 1
cPLA2 (human) sFDDDELDAAVADPD D522
cPLA2 (mouse) DsFDDELdAAVADPD D521-ca
cPLA2 (rat) sFDDDELDAAVADPD D522
Y534-p
PDEFERIyEPLDVKS
0 33
cPLA2 (human) PDEFERIyEPLDVkS Y535-p
cPLA2 (mouse) PDEFERIyEPLDVKS Y534-p
cPLA2 (rat) PDEFERIYEPLDVKS Y535
K540
IyEPLDVKSKKIHVV
0 4
cPLA2 (human) IyEPLDVkSKKIHVV K541-ub
cPLA2 (mouse) IyEPLDVKSKKIHVV K540
cPLA2 (rat) IYEPLDVKSKKIHVV K541
K540
IyEPLDVKSKKIHVV
0 1
cPLA2 (human) IyEPLDVkSKKIHVV K541-sm
cPLA2 (mouse) IyEPLDVKSKKIHVV K540
cPLA2 (rat) IYEPLDVKSKKIHVV K541
K594
KELLLAEKWAKMNKL
0 1
cPLA2 (human) KELLLAEkWAKMNKL K595-ub
cPLA2 (mouse) KELLLAEKWAKMNKL K594
cPLA2 (rat) KELLLAEKWAKMNKL K595
K605
MNKLPFPKIDPYVFD
0 1
cPLA2 (human) MNKLPFPkIDPYVFD K606-ub
cPLA2 (mouse) MNKLPFPKIDPYVFD K605
cPLA2 (rat) MNKLPFPKIDPYVFD K606
K617
VFDREGLKECYVFKP
0 1
cPLA2 (human) VFDREGLkECYVFKP K618-ub
cPLA2 (mouse) VFDREGLKECYVFKP K617
cPLA2 (rat) VFDREGLKECYVFKP K618
K690-ac
QYPNQAFkRLHDLMY
0 1
cPLA2 (human) QYPNQAFKRLHDLMH K691
cPLA2 (mouse) QYPNQAFkRLHDLMY K690-ac
cPLA2 (rat) QYPNQAFKRLHDLMY K691
K690
QYPNQAFKRLHDLMY
0 1
cPLA2 (human) QYPNQAFkRLHDLMH K691-ub
cPLA2 (mouse) QYPNQAFKRLHDLMY K690
cPLA2 (rat) QYPNQAFKRLHDLMY K691
S714
IKDAIVESIEYRRQN
0 1
cPLA2 (human) IKEAMVEsIEyRRQN S715-p
cPLA2 (mouse) IKDAIVESIEYRRQN S714
cPLA2 (rat) IKDAIVESIEYRRQN S715
Y717
AIVESIEYRRQNPsR
0 1
cPLA2 (human) AMVEsIEyRRQNPsR Y718-p
cPLA2 (mouse) AIVESIEYRRQNPsR Y717
cPLA2 (rat) AIVESIEYRRQNPSR Y718
S723-p
EYRRQNPsRCsVsLs
Upstream
0 4
Treatment
  • IL-33
cPLA2 (human) EyRRQNPsRCsVsLS S724-p
cPLA2 (mouse) EYRRQNPsRCsVsLs S723-p
cPLA2 (rat) EYRRQNPSRCsVsLS S724
S726-p
RQNPsRCsVsLsNVE
Upstream
Downstream
8 33
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • MAPKAPK5 (mouse)
  • Mnk1 (mouse)
  • MSK1 (mouse)
Putative in vivo kinases:
  • Mnk1 (mouse)
Treatment
  • A23187
  • IL-33
  • insulin
  • ischemia
  • MK-2206
  • NAG-thiazoline
  • okadaic_acid
  • PUGNAc
cPLA2 (human) RQNPsRCsVsLSNVE S727-p
cPLA2 (mouse) RQNPsRCsVsLsNVE S726-p
cPLA2 (rat) RQNPSRCsVsLSNVE S727-p
S728-p
NPsRCsVsLsNVEAR
Upstream
0 32
Regulatory protein:
  • MPRIP (mouse)
Treatment
  • insulin
  • ischemia
  • MK-2206
  • NAG-thiazoline
  • okadaic_acid
  • PUGNAc
cPLA2 (human) NPsRCsVsLSNVEAR S729-p
cPLA2 (mouse) NPsRCsVsLsNVEAR S728-p
cPLA2 (rat) NPSRCsVsLSNVEAR S729-p
S730-p
sRCsVsLsNVEARKF
0 1
cPLA2 (human) sRCsVsLSNVEARRF S731
cPLA2 (mouse) sRCsVsLsNVEARKF S730-p
cPLA2 (rat) SRCsVsLSNVEARKF S731
K740
EARKFFNKEFLSKPT
0 1
cPLA2 (human) EARRFFNkEFLSKPK K741-ub
cPLA2 (mouse) EARKFFNKEFLSKPT K740
cPLA2 (rat) EARKFFNKEFLSKPT K741
-
gap
0 1
cPLA2 (human) gap -
cPLA2 (mouse) gap -
cPLA2 (rat) LSKPTAEsI______ S751-p